EXEL vs GH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
EXEL shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics.
Guardant Health presents a classic high-growth, pre-profitability profile, evidenced by a stable but mediocre Piotroski F-Score of 4/9. While the company demonstrates impressive top-line momentum with 39.4% YoY revenue growth and a strong current ratio of 4.84, it continues to operate with significant negative margins and negative shareholder equity. The stark divergence between the 'Strong Buy' analyst consensus and the bearish insider selling suggests a disconnect between institutional growth projections and internal sentiment. Overall, the stock is a speculative growth play where valuation is driven by future market penetration rather than current fundamental value.
Compare Another Pair
Related Comparisons
EXEL vs GH: Head-to-Head Comparison
This page compares Exelixis, Inc. (EXEL) and Guardant Health, Inc. (GH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.